Skip to search formSkip to main contentSkip to account menu

60 ACTUAT olodaterol 0.0025 MG/ACTUAT / tiotropium 0.0025 MG/ACTUAT Metered Dose Inhaler

Known as: tiotropium bromide 2.5 MCG / olodaterol 2.5 MCG per INHAL Metered Dose Inhaler, 60 ACTUAT, OLODATEROL 2.5MCG/TIOTROPIUM 2.5MCG/ACTUAT INHL,ORAL,60D,4GM [VA Product], OLODATEROL/TIOTROP 2.5MCG/ACTUAT 60D INH 
National Institutes of Health

Related topics

Related topics

5 relations
AsthmaMetered Dose Inhalerolodaterololodaterol / tiotropium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies
Chronic obstructive pulmonary disease is associated with significant morbidity and mortality. Trials of maintenance chronic… 
2016
2016
Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands
Purpose The fixed-dose dual bronchodilator combination (FDC) of tiotropium and olodaterol showed increased effectiveness… 
Review
2015
Review
2015
▼Olodaterol—another LABA for COPD
▼Olodaterol solution for inhalation (Striverdi Respimat—Boehringer Ingelheim) is a long-acting beta2 agonist (LABA) licensed for… 
2015
2015
Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study
BackgroundOlodaterol is a novel, inhaled long-acting β2-agonist (LABA) with >24-h duration of action investigated in asthma and… 
2015
2015
The 24h lung-function pro fi le of once-daily tiotropium and olodaterol fi xed-dose combination in chronic obstructive pulmonary disease
Background: This study investigated the effects on 24-h lung function and lung volume of a once-daily fixed-dose combination (FDC… 
2014
2014
The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies
These studies evaluated the 24-h forced expiratory volume in 1 sec (FEV1) profile of once-daily (QD) olodaterol compared to… 
2013
2013
P230 Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: combined analysis from two 48-week studies
Background The novel LABA olodaterol has 24-h bronchodilator activity. Objective To evaluate the symptomatic benefit of… 
2013
2013
48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis
Background: The novel LABA olodaterol (O) has an acceptable safety profile in clinical studies of ≤4 weeks (wks). Objective: To… 
2013
2013
Struktur und Funktion β-adrenerger Rezeptoren Structure and function of β-adrenergic receptors
fische Verteilung der Rezeptorsubtypen vorzuliegen, sondern vielmehr eine unterschiedliche Dichte der Rezeptorsubtypen in den… 
Highly Cited
2011
Highly Cited
2011
24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)